Trials / Completed
CompletedNCT01397929
An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors
An Open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- Basilea Pharmaceutica · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
First in human, open-label, sequential dose escalation and expansion study of intravenous BAL101553 in adult patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BAL101553 | Intravenous administration |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2016-01-01
- Completion
- 2016-04-01
- First posted
- 2011-07-20
- Last updated
- 2023-05-10
Locations
3 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01397929. Inclusion in this directory is not an endorsement.